

# Wagner F Gattaz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11228043/publications.pdf>

Version: 2024-02-01

165  
papers

9,866  
citations

26630

56  
h-index

39675

94  
g-index

167  
all docs

167  
docs citations

167  
times ranked

10473  
citing authors

#	ARTICLE	IF	CITATIONS
1	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: An updated systematic review and meta-analysis. <i>World Journal of Biological Psychiatry</i> , 2023, 24, 24-33.	2.6	10
2	COX-2 pathway is upregulated in ultra-high risk individuals for psychosis. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 236-241.	2.6	2
3	Antipsychotics preserve telomere length in peripheral blood mononuclear cells after acute oxidative stress injury. <i>Neural Regeneration Research</i> , 2022, 17, 1156.	3.0	3
4	The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2022, 308, 71-75.	4.1	4
5	Lithium increases cortical and subcortical volumes in subjects with bipolar disorder. <i>Psychiatry Research - Neuroimaging</i> , 2022, 324, 111494.	1.8	2
6	Increased PLA2 activity in individuals at ultra-high risk for psychosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1593-1599.	3.2	2
7	Genetic polymorphisms of the serotonin transporter are not related with depression in temporal lobe epilepsy caused by hippocampal sclerosis. <i>Epilepsy and Behavior</i> , 2021, 117, 107854.	1.7	0
8	Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial. <i>Schizophrenia Research</i> , 2021, 235, 44-51.	2.0	7
9	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 483-488.	3.2	10
10	Reduced Annexin A3 in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 489-494.	3.2	9
11	Differences in the immune-inflammatory profiles of unipolar and bipolar depression. <i>Journal of Affective Disorders</i> , 2020, 262, 8-15.	4.1	55
12	Cognitive changes after tDCS and escitalopram treatment in major depressive disorder: Results from the placebo-controlled ELECT-TDCS trial. <i>Journal of Affective Disorders</i> , 2020, 263, 344-352.	4.1	13
13	Clinical and biological effects of long-term lithium treatment in older adults with amnesic mild cognitive impairment: randomised clinical trial. <i>British Journal of Psychiatry</i> , 2019, 215, 668-674.	2.8	91
14	Plasma metabolites in first episode psychoses. <i>Schizophrenia Research</i> , 2019, 206, 468-470.	2.0	6
15	Transcranial direct current stimulation (tDCS) for preventing major depressive disorder relapse: Results of a 6-month follow-up. <i>Depression and Anxiety</i> , 2019, 36, 262-268.	4.1	31
16	Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 190-196.	2.6	18
17	Decreased plasmatic spermidine and increased spermine in mild cognitive impairment and Alzheimer's disease patients. <i>Revista De Psiquiatria Clinica</i> , 2019, 46, 120-124.	0.6	15
18	Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression. <i>JAMA Psychiatry</i> , 2018, 75, 158.	11.0	98

#	ARTICLE	IF	CITATIONS
19	Genetic polymorphisms of the 5HT receptors are not related with depression in temporal lobe epilepsy caused by hippocampal sclerosis. <i>Epilepsy and Behavior</i> , 2018, 83, 181-185.	1.7	6
20	Increased platelet glycogen synthase kinase 3beta in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 195, 402-405.	2.0	4
21	Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 501-507.	3.2	13
22	Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 211-217.	4.8	40
23	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 82-90.	2.4	61
24	Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 40-45.	1.4	64
25	Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes. <i>JAMA Psychiatry</i> , 2017, 74, 143.	11.0	355
26	Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. <i>New England Journal of Medicine</i> , 2017, 376, 2523-2533.	27.0	284
27	The Bipolar Illness Onset study: research protocol for the BIO cohort study. <i>BMJ Open</i> , 2017, 7, e015462.	1.9	119
28	Stereological investigation of the CA1 pyramidal cell layer in untreated and lithium-treated 3xTg-AD and wild-type mice. <i>Annals of Anatomy</i> , 2017, 209, 51-60.	1.9	14
29	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 330-356.	2.6	33
30	Glycogen synthase kinase-3 $\beta$ in patients with bipolar I disorder: results from a prospective study. <i>Bipolar Disorders</i> , 2016, 18, 334-341.	1.9	8
31	Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. <i>Bipolar Disorders</i> , 2016, 18, 63-70.	1.9	32
32	Long-term lithium treatment increases intracellular and extracellular brain-derived neurotrophic factor (BDNF) in cortical and hippocampal neurons at subtherapeutic concentrations. <i>Bipolar Disorders</i> , 2016, 18, 692-695.	1.9	33
33	Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. <i>NeuroImage: Clinical</i> , 2016, 12, 1-15.	2.7	107
34	Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 607-618.	3.2	8
35	Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. <i>Schizophrenia Research</i> , 2016, 177, 67-69.	2.0	11
36	Lithium Distinctly Modulates the Secretion of Pro- and Anti- Inflammatory Interleukins in Co-Cultures of Neurons and Glial Cells at Therapeutic and Sub-Therapeutic Concentrations. <i>Current Alzheimer Research</i> , 2016, 13, 848-852.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. <i>European Neuropsychopharmacology</i> , 2015, 25, 468-473.	0.7	65
38	Hippocampal serotonin depletion is related to the presence of generalized tonic-clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy. <i>Epilepsy Research</i> , 2015, 111, 18-25.	1.6	18
39	Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. <i>Human Psychopharmacology</i> , 2015, 30, 52-56.	1.5	26
40	Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial. <i>Journal of Affective Disorders</i> , 2015, 185, 209-213.	4.1	24
41	Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue. <i>Journal of Neural Transmission</i> , 2015, 122, 1371-1380.	2.8	22
42	BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: A systematic review and meta-analysis. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 114-122.	2.6	44
43	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 142-170.	2.6	106
44	Lithium increases platelet serine-9 phosphorylated GSK-3 $\beta$ levels in drug-free bipolar disorder during depressive episodes. <i>Journal of Psychiatric Research</i> , 2015, 62, 78-83.	3.1	47
45	Bimodal Effect of Lithium Plasma Levels on Hippocampal Glutamate Concentrations in Bipolar II Depression: A Pilot Study. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	2.1	18
46	A Longitudinal (6-week) 3T 1H-MRS Study on the Effects of Lithium Treatment on Anterior Cingulate Cortex Metabolites in Bipolar Depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 2311-2317.	0.7	50
47	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 455-463.	2.4	77
48	Regulation of leukocyte tricarboxylic acid cycle in drug-naïve Bipolar Disorder. <i>Neuroscience Letters</i> , 2015, 605, 65-68.	2.1	12
49	Chronic inhibition of brain phospholipase A2 in adult rats impairs the survival of newborn mature neurons in the hippocampus. <i>Journal of Neural Transmission</i> , 2015, 122, 619-628.	2.8	3
50	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 91-96.	4.8	32
51	Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. <i>Psychopharmacology</i> , 2015, 232, 245-250.	3.1	51
52	Reduced activities of phospholipases A <sub>2</sub> in platelets of drug-naïve bipolar disorder patients. <i>Bipolar Disorders</i> , 2015, 17, 97-101.	1.9	10
53	Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 243-246.	4.8	27
54	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: A systematic review and meta-analysis. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 411-418.	2.6	89

#	ARTICLE	IF	CITATIONS
55	Reduced Cerebrospinal Fluid Levels of Brain-Derived Neurotrophic Factor Is Associated With Cognitive Impairment in Late-Life Major Depression. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2014, 69, 845-851.	3.9	54
56	Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients. <i>Advances in Biological Psychiatry</i> , 2014, , 1-1.	0.2	0
57	Synergistic and additive effects of enriched environment and lithium on the generation of new cells in adult mouse hippocampus. <i>Journal of Neural Transmission</i> , 2014, 121, 695-706.	2.8	4
58	Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2014, 121, 193-200.	2.8	26
59	Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. <i>Psychopharmacology</i> , 2014, 231, 1315-1323.	3.1	52
60	Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. <i>Journal of Psychiatric Research</i> , 2014, 50, 36-41.	3.1	135
61	Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. <i>Journal of Psychiatric Research</i> , 2014, 55, 96-100.	3.1	24
62	Long-Term Lithium Treatment Reduces Glucose Metabolism in the Cerebellum and Hippocampus of Nondemented Older Adults: An [ <sup>18</sup> F]FDG-PET Study. <i>ACS Chemical Neuroscience</i> , 2014, 5, 484-489.	3.5	19
63	BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: Results from a factorial, randomized, sham-controlled trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1144-1151.	0.7	42
64	Leukocyte mitochondrial DNA copy number in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 48, 32-35.	4.8	57
65	Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1205-1208.	1.8	19
66	Long-Term, Low-Dose Lithium Treatment Does Not Impair Renal Function in the Elderly. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e672-e678.	2.2	67
67	Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 115-121.	3.4	119
68	Bcl-2 rs956572 Polymorphism is Associated with Increased Anterior Cingulate Cortical Glutamate in Euthymic Bipolar I Disorder. <i>Neuropsychopharmacology</i> , 2013, 38, 468-475.	5.4	65
69	Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia. <i>Journal of Neural Transmission</i> , 2013, 120, 187-195.	2.8	19
70	Correlation between platelet and brain PLA2 activity. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 89, 265-268.	2.2	7
71	Reduced Serum Nerve Growth Factor in Patients With Late-Life Depression. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 493-496.	1.2	65
72	Early improvement with lithium in classic mania and its association with later response. <i>Journal of Affective Disorders</i> , 2013, 144, 160-164.	4.1	22

#	ARTICLE	IF	CITATIONS
73	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 2-44.	2.6	343
74	Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype. <i>Clinics</i> , 2013, 68, 277-280.	1.5	19
75	Mild cognitive impairment (part 1): clinical characteristics and predictors of dementia. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 178-185.	1.7	42
76	A radioenzymatic assay to identify three groups of phospholipase A2 in platelets. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2012, 86, 149-153.	2.2	10
77	Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. <i>Journal of Psychiatric Research</i> , 2012, 46, 1053-1058.	3.1	20
78	Reduced serum levels of adiponectin in elderly patients with major depression. <i>Journal of Psychiatric Research</i> , 2012, 46, 1081-1085.	3.1	74
79	Does Lithium Prevent Alzheimer's Disease?. <i>Drugs and Aging</i> , 2012, 29, 335-342.	2.7	122
80	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 318-378.	2.6	498
81	Inhibition of cPLA <sub>2</sub> and sPLA <sub>2</sub> Activities in Primary Cultures of Rat Cortical Neurons by <i>Centella asiatica</i> Water Extract. <i>Natural Product Communications</i> , 2012, 7, 1934578X1200700.	0.5	9
82	Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 815-819.	2.8	43
83	Does BDNF genotype influence creative output in bipolar I manic patients?. <i>Journal of Affective Disorders</i> , 2012, 139, 181-186.	4.1	16
84	Circulating Glial-derived neurotrophic factor is reduced in late-life depression. <i>Journal of Psychiatric Research</i> , 2012, 46, 135-139.	3.1	58
85	Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: A preliminary 4-week study. <i>Neuroscience Letters</i> , 2011, 494, 54-56.	2.1	125
86	Inhibition of phospholipase A2 in rat brain modifies different membrane fluidity parameters in opposite ways. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1612-1617.	4.8	21
87	Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2011, 45, 220-224.	3.1	88
88	Increased PLA2 activity in the hippocampus of patients with temporal lobe epilepsy and psychosis. <i>Journal of Psychiatric Research</i> , 2011, 45, 1617-1620.	3.1	20
89	Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein. <i>Journal of Neural Transmission</i> , 2011, 118, 1273-1279.	2.8	22
90	Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2011, 198, 351-356.	2.8	319

#	ARTICLE	IF	CITATIONS
91	Effects of lithium on oxidative stress parameters in healthy subjects. <i>Molecular Medicine Reports</i> , 2011, 5, 680-2.	2.4	94
92	What Does Proteomics Tell Us About Schizophrenia?. , 2011, , 345-366.		1
93	Diagnosis and biomarkers of predementia in Alzheimer's disease. <i>BMC Medicine</i> , 2010, 8, 89.	5.5	95
94	Exploring the knowledge contained in neuroimages: Statistical discriminant analysis and automatic segmentation of the most significant changes. <i>Artificial Intelligence in Medicine</i> , 2010, 49, 105-115.	6.5	6
95	Clinical and biological predictors of Alzheimer's disease in patients with amnesic mild cognitive impairment. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 216-222.	1.7	49
96	Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia. <i>Clinics</i> , 2010, 65, 539-546.	1.5	6
97	Inhibition of phospholipase A2 increases Tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2010, 82, 57-60.	2.2	15
98	Differential roles of phospholipases A2 in neuronal death and neurogenesis: Implications for Alzheimer disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1381-1389.	4.8	29
99	Proteome analysis of schizophrenia brain tissue. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 110-120.	2.6	82
100	Genetic and Proteomic Studies in Schizophrenia. , 2010, , 193-218.		0
101	Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. <i>Journal of Psychiatric Research</i> , 2009, 43, 978-986.	3.1	165
102	Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. <i>Journal of Neural Transmission</i> , 2009, 116, 275-289.	2.8	137
103	Stereologic investigation of the posterior part of the hippocampus in schizophrenia. <i>Acta Neuropathologica</i> , 2009, 117, 395-407.	7.7	146
104	Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 151-163.	3.2	180
105	Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. <i>Psychopharmacology</i> , 2009, 202, 37-51.	3.1	60
106	Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. <i>BMC Psychiatry</i> , 2009, 9, 17.	2.6	133
107	Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: Preliminary evidence. <i>Psychiatry Research</i> , 2009, 165, 1-9.	3.3	61
108	Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. <i>Psychopharmacology</i> , 2008, 198, 1-27.	3.1	82

#	ARTICLE	IF	CITATIONS
109	World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2008, 100, 20-38.	2.0	240
110	Cognitive training increases platelet PLA2 activity in healthy elderly subjects. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2008, 78, 265-269.	2.2	25
111	Mild cognitive impairment: cognitive screening or neuropsychological assessment?. <i>Revista Brasileira De Psiquiatria</i> , 2008, 30, 316-321.	1.7	63
112	Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. <i>British Journal of Psychiatry</i> , 2007, 190, 359-360.	2.8	323
113	Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2007, 76, 47-55.	2.2	38
114	Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. <i>Psychopharmacology</i> , 2007, 192, 547-553.	3.1	49
115	Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 340-343.	3.2	30
116	Analysis of coding-polymorphisms in NOTCH-related genes reveals NUMBL poly-glutamine repeat to be associated with schizophrenia in Brazilian and Danish subjects. <i>Schizophrenia Research</i> , 2006, 88, 275-282.	2.0	15
117	Complex slow potential generators in a simplified attention paradigm. <i>International Journal of Psychophysiology</i> , 2006, 61, 149-157.	1.0	11
118	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo. <i>Revista De Psiquiatria Clinica</i> , 2006, 33, 7-64.	0.6	9
119	The Short Cognitive Performance Test (SKT): a preliminary study of its psychometric properties in Brazil. <i>International Psychogeriatrics</i> , 2006, 18, 121-133.	1.0	51
120	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 5-40.	2.6	194
121	Reduced phospholipid breakdown in Alzheimer's brains: a 31P spectroscopy study. <i>Psychopharmacology</i> , 2005, 180, 359-365.	3.1	45
122	Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. <i>Psychopharmacology</i> , 2005, 181, 392-400.	3.1	53
123	Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2005, 162, 1879-1887.	7.2	129
124	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 132-191.	2.6	242
125	Nogo CAA 3'UTR Insertion polymorphism is not associated with Schizophrenia nor with bipolar disorder. <i>Schizophrenia Research</i> , 2005, 75, 5-9.	2.0	18
126	Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. <i>Schizophrenia Research</i> , 2004, 66, 97-100.	2.0	65



#	ARTICLE	IF	CITATIONS
127	Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. <i>Biological Psychiatry</i> , 2004, 56, 41-45.	1.3	111
128	Widespread electrical cortical dysfunction in schizophrenia. <i>Schizophrenia Research</i> , 2004, 69, 255-266.	2.0	8
129	Rightward cerebral asymmetry in subtypes of schizophrenia according to Leonhard's classification and to DSM-IV: a structural MRI study. <i>Psychiatry Research - Neuroimaging</i> , 2003, 123, 65-79.	1.8	23
130	Increased phospholipase A2 activity in schizophrenia with absent response to niacin. <i>Schizophrenia Research</i> , 2003, 61, 1-6.	2.0	104
131	The generators of slow potentials obtained during verbal, pictorial and spatial tasks. <i>International Journal of Psychophysiology</i> , 2003, 48, 55-65.	1.0	11
132	Reduced Cortical Folding in Schizophrenia: An MRI Morphometric Study. <i>American Journal of Psychiatry</i> , 2003, 160, 1606-1613.	7.2	130
133	Multifocal slow potential generation revealed by high-resolution EEG and current density reconstruction. <i>International Journal of Psychophysiology</i> , 2002, 45, 227-240.	1.0	16
134	Lack of association between schizophrenia and the phospholipase-A2 genes cPLA2 and sPLA2. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 246-249.	2.4	38
135	Decreased S100-beta protein in schizophrenia: preliminary evidence. <i>Schizophrenia Research</i> , 2000, 43, 91-95.	2.0	57
136	Neuroquímica da esquizofrenia: papel dos fosfolípidos. <i>Revista Brasileira De Psiquiatria</i> , 2000, 22, 5-8.	1.7	5
137	Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1996, 55, 109-113.	2.2	44
138	Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: acceptability, reliability and validity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1996, 246, 71-77.	3.2	2
139	Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: Possible implications for schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1995, 246, 13-16.	3.2	13
140	Decreased phospholipase A2 activity in Alzheimer brains. <i>Biological Psychiatry</i> , 1995, 37, 13-17.	1.3	100
141	Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats. <i>Psychiatry Research</i> , 1995, 58, 165-169.	3.3	7
142	Basal ganglia abnormalities in tardive dyskinesia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1994, 244, 272-277.	3.2	30
143	Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. <i>Biological Psychiatry</i> , 1994, 36, 137-139.	1.3	96
144	Assessment of tardive dyskinesia by means of digital image processing. <i>Psychopharmacology</i> , 1993, 111, 278-284.	3.1	12

#	ARTICLE	IF	CITATIONS
145	Phospholipase A2 in Schizophrenia. <i>Biological Psychiatry</i> , 1992, 31, 214-216.	1.3	10
146	Hypofrontality on topographic EEG in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 241, 328-332.	3.2	95
147	The deleterious effect of ocular artefacts on the quantitative EEG, and a remedy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 241, 352-356.	3.2	66
148	An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia. <i>Psychiatry Research</i> , 1991, 38, 125-134.	3.3	166
149	Increased platelet membrane lysophosphatidylcholine in schizophrenia. <i>Biological Psychiatry</i> , 1991, 30, 837-840.	1.3	58
150	Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1991, 241, 65-68.	3.2	91
151	Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics. <i>Biological Psychiatry</i> , 1989, 25, 247-255.	1.3	15
152	CT scans and neuroleptic response in schizophrenia: A multidimensional approach. <i>Psychiatry Research</i> , 1988, 26, 293-303.	3.3	22
153	Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. <i>Biological Psychiatry</i> , 1987, 22, 421-426.	1.3	208
154	Bromocriptine in the treatment of neuroleptic-resistant schizophrenia. <i>Biological Psychiatry</i> , 1986, 21, 519-521.	1.3	13
155	Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. <i>Psychoneuroendocrinology</i> , 1985, 10, 187-191.	2.7	121
156	Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. <i>Biological Psychiatry</i> , 1985, 20, 360-366.	1.3	71
157	A possible association between HLA B-27 and vulnerability to schizophrenia. <i>Personality and Individual Differences</i> , 1985, 6, 283-285.	2.9	11
158	CSF Studies in Schizophrenia: A Multidimensional Approach. , 1985, , 144-153.		0
159	Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. <i>Psychiatry Research</i> , 1983, 8, 243-250.	3.3	55
160	Glutamate in schizophrenics and healthy controls. <i>Archiv Fur Psychiatrie Und Nervenkrankheiten</i> , 1982, 231, 221-225.	0.6	50
161	Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls. <i>Archiv Fur Psychiatrie Und Nervenkrankheiten</i> , 1982, 232, 463-471.	0.6	25
162	HLA-B27 as a possible genetic marker of psychoticism. <i>Personality and Individual Differences</i> , 1981, 2, 57-60.	2.9	15

#	ARTICLE	IF	CITATIONS
163	HLA antigens and schizophrenia: A pool of two studies. Psychiatry Research, 1981, 5, 123-128.	3.3	48
164	The HLA system and schizophrenia. Archiv Fur Psychiatrie Und Nervenkrankheiten, 1980, 228, 205-211.	0.6	19
165	HLA-Antigens, Schizophrenia and Brain Atrophy. British Journal of Psychiatry, 1980, 137, 398-399.	2.8	2